ALK and non-small cell lung carcinoma: Brigatinib, like alectinib and ceritinib, was granted accelerated FDA approval, in 2017, for treatment of patients with ALK+ metastatic NSCLC, whose disease progressed on or who were intolerant of crizotinib.